DK2512240T3 - Methods and compositions for the treatment and improvement of trigeminal autonomic cephalgias, migraines and vascular conditions - Google Patents

Methods and compositions for the treatment and improvement of trigeminal autonomic cephalgias, migraines and vascular conditions Download PDF

Info

Publication number
DK2512240T3
DK2512240T3 DK10838320.9T DK10838320T DK2512240T3 DK 2512240 T3 DK2512240 T3 DK 2512240T3 DK 10838320 T DK10838320 T DK 10838320T DK 2512240 T3 DK2512240 T3 DK 2512240T3
Authority
DK
Denmark
Prior art keywords
composition
pain
migraine
ketoprofen
headache
Prior art date
Application number
DK10838320.9T
Other languages
Danish (da)
English (en)
Inventor
Harry J Leighton
Matthew J Buderer
Crist J Frangakis
Original Assignee
Achelios Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achelios Therapeutics Inc filed Critical Achelios Therapeutics Inc
Application granted granted Critical
Publication of DK2512240T3 publication Critical patent/DK2512240T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK10838320.9T 2009-12-18 2010-12-17 Methods and compositions for the treatment and improvement of trigeminal autonomic cephalgias, migraines and vascular conditions DK2512240T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28795309P 2009-12-18 2009-12-18
PCT/US2010/061130 WO2011075688A1 (en) 2009-12-18 2010-12-17 Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions

Publications (1)

Publication Number Publication Date
DK2512240T3 true DK2512240T3 (en) 2018-07-16

Family

ID=44167727

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10838320.9T DK2512240T3 (en) 2009-12-18 2010-12-17 Methods and compositions for the treatment and improvement of trigeminal autonomic cephalgias, migraines and vascular conditions

Country Status (9)

Country Link
US (2) US20130109674A1 (cg-RX-API-DMAC7.html)
EP (1) EP2512240B1 (cg-RX-API-DMAC7.html)
JP (2) JP6200648B2 (cg-RX-API-DMAC7.html)
AU (2) AU2010330747B2 (cg-RX-API-DMAC7.html)
CA (1) CA2784824A1 (cg-RX-API-DMAC7.html)
DK (1) DK2512240T3 (cg-RX-API-DMAC7.html)
ES (1) ES2677352T3 (cg-RX-API-DMAC7.html)
IL (2) IL220464A (cg-RX-API-DMAC7.html)
WO (1) WO2011075688A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9629920B2 (en) 2009-12-18 2017-04-25 Exodos Life Sciences Limited Partnership Methods and compositions for stable liquid drug formulations
US9192637B1 (en) * 2011-09-23 2015-11-24 Natural Fibers Corporation Milkweed seed oil administered to animals
WO2013074517A1 (en) * 2011-11-14 2013-05-23 Roswell Park Cancer Institute Kinase protein binding inhibitors
US8822537B2 (en) * 2012-09-27 2014-09-02 Achelios Therapeutics, Inc. Topical ketoprofen composition
JP2016503410A (ja) * 2012-11-09 2016-02-04 スリーイー セラピューティクス コーポレイション３Ｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｘ線造影剤組成物およびそれを使用して炎症関連症状を治療する方法
EP2964257B1 (en) * 2013-03-08 2024-10-09 Research Institute at Nationwide Children's Hospital Transcutaneous dosage formulation
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9011934B2 (en) 2013-06-14 2015-04-21 SatisPharma, LLC Multi-purpose anti-itch treatment
EP3096721A4 (en) * 2014-01-22 2017-10-18 Marcio Marc Abreu Devices configured to provide treatment at an abreu brain thermal tunnel
US9452178B1 (en) 2014-10-22 2016-09-27 SatisPharma, LLC Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations
WO2016089893A1 (en) * 2014-12-01 2016-06-09 Achelios Therapeutics Inc. Methods and compositions for treating migraine and conditions associated with pain
US11007161B1 (en) 2014-12-31 2021-05-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films
US10596117B1 (en) 2014-12-31 2020-03-24 Eric Morrison Lipoleosomes as carriers for aromatic amide anesthetic compounds
US10561627B2 (en) 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
BR112017020307B1 (pt) 2015-03-26 2023-11-07 Jacqueline M. Iversen Usos de uma combinação de naproxeno e fexofenadina
WO2017024214A1 (en) * 2015-08-05 2017-02-09 Synergistic Therapeutics, Llc Topical analgesis loton
US20190105260A1 (en) * 2016-03-22 2019-04-11 The Regents Of The University Of California Compositions and methods to promote wound healing
JP7024248B2 (ja) * 2016-09-01 2022-02-24 大正製薬株式会社 固形製剤
CA3063870A1 (en) * 2017-05-15 2018-11-22 Biochemics, Inc. Transdermally-delivered combination drug therapy for pain
JP7673337B2 (ja) * 2019-11-07 2025-05-09 アリナミン製薬株式会社 医薬組成物
EP3900715A1 (en) * 2020-04-21 2021-10-27 Dompe' Farmaceutici S.P.A. Synergistic admixtures of gabapentin and ketoprofen, pharmaceutical compositions and their medical use
EP3900716A1 (en) * 2020-04-21 2021-10-27 Dompe' Farmaceutici S.P.A. Co-crystal of gabapentin, ketoprofen and lysine, pharmaceutical compositions and their medical use
WO2023073457A1 (en) * 2021-10-30 2023-05-04 Mousavi Mirzaei Seyed Mohammad A topical pain-relief medicine for relieving headache

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877805A (en) 1985-07-26 1989-10-31 Kligman Albert M Methods for treatment of sundamaged human skin with retinoids
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
CA1237671A (en) 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
US5409704A (en) 1985-06-26 1995-04-25 The Liposome Company, Inc. Liposomes comprising aminoglycoside phosphates and methods of production and use
US5023087A (en) 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
IE60901B1 (en) 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5032582A (en) 1987-02-27 1991-07-16 Liposome Technology, Inc. Method for treating fungal infections with amphotericin B/cholesterol sulfate composition
US4994213A (en) 1988-05-17 1991-02-19 Liposome Technology, Inc. Method of preparing lipid structures
US4980378A (en) 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
US5082866A (en) 1988-06-01 1992-01-21 Odontex, Inc. Biodegradable absorption enhancers
US5194266A (en) 1989-08-08 1993-03-16 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition and method
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
CA2108288C (en) 1991-04-19 2003-09-16 Jill P. Adler-Moore Liposomal cyclosporin formulation and process for the preparation thereof
GR1002207B (en) 1992-08-06 1996-03-27 Johnson & Johnson Consumer Skin care compositions containing imidazoles.
US5552155A (en) 1992-12-04 1996-09-03 The Liposome Company, Inc. Fusogenic lipsomes and methods for making and using same
AU5938996A (en) 1995-06-07 1996-12-30 Nexstar Pharmaceuticals, Inc. Method for encapsulating pharmaceutical materials
US6387407B1 (en) * 1995-09-29 2002-05-14 L.A.M. Pharmaceutical Corporation Topical drug preparations
US5897880A (en) * 1995-09-29 1999-04-27 Lam Pharmaceuticals, Llc. Topical drug preparations
ATE334689T1 (de) * 1995-11-13 2006-08-15 Univ Northwest Verabreichungsmedium für analgetische, entzündungshemmende und antipyretische wirkstoffe und pharmazeutische zusammensetzungen enthaltend solches medium und wirkstoffe
US6083996A (en) 1997-11-05 2000-07-04 Nexmed Holdings, Inc. Topical compositions for NSAI drug delivery
US6139861A (en) * 1999-01-14 2000-10-31 Friedman; Mark Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache facial pain, and cervical-muscle spasm
US6118020A (en) * 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
US6642243B1 (en) * 1999-07-22 2003-11-04 Ashkan Imanzahrai Migraine medicine and method for treating same
US20020143047A1 (en) * 2001-01-05 2002-10-03 Galer Bradley S. Methods for treating indomethacin responsive headaches
US20070112052A9 (en) * 2001-01-05 2007-05-17 Larry Caldwell Methods and compositions for treating headache pain with topical NSAID compositions
DE60228294D1 (en) * 2001-06-05 2008-09-25 Ronald Aung-Din Topische migränetherapie
US20040138239A1 (en) * 2001-08-23 2004-07-15 Bruce Frome Compositions and methods for targeting cerebral circulation and treatment of headache
WO2003077847A2 (en) * 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
WO2004075832A2 (en) * 2003-02-27 2004-09-10 Lucas John M Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
US7357950B2 (en) * 2003-03-21 2008-04-15 Elizabeth Anne Mazzio Topical treatment for dyshidrosis (pompholyx) and dry skin disorders
US20050095277A1 (en) * 2003-06-25 2005-05-05 Binnur Ozturk Neuropathy cream
US20050019354A1 (en) * 2003-07-23 2005-01-27 Perricone Nicholas V. Topical benfotiamine treatments
AU2005210668A1 (en) * 2004-01-30 2005-08-18 Angiotech International Ag Compositions and methods for treating contracture
AU2005235308B2 (en) * 2004-04-19 2011-12-01 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US7749515B2 (en) * 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
WO2006122123A2 (en) * 2005-05-09 2006-11-16 Levin Bruce H Methods of alleviating disorders and their associated pain
WO2007025249A2 (en) * 2005-08-26 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
JP5129752B2 (ja) * 2005-11-18 2013-01-30 メルク・シャープ・エンド・ドーム・コーポレイション スピロヒダントイン三環式ｃｇｒｐ受容体アンタゴニスト
US20090312435A1 (en) * 2006-08-30 2009-12-17 Auspex Pharmaceuticals, Inc Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity

Also Published As

Publication number Publication date
JP2016155817A (ja) 2016-09-01
EP2512240A4 (en) 2014-05-07
AU2010330747A1 (en) 2012-08-02
ES2677352T3 (es) 2018-08-01
AU2016256779B2 (en) 2018-11-01
US20190105290A1 (en) 2019-04-11
AU2010330747B2 (en) 2016-08-11
IL220464A (en) 2017-10-31
CA2784824A1 (en) 2011-06-23
EP2512240A1 (en) 2012-10-24
AU2016256779A1 (en) 2016-12-01
IL255044A0 (en) 2017-12-31
EP2512240B1 (en) 2018-04-11
WO2011075688A1 (en) 2011-06-23
JP2013515002A (ja) 2013-05-02
JP6200648B2 (ja) 2017-09-20
US20130109674A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
DK2512240T3 (en) Methods and compositions for the treatment and improvement of trigeminal autonomic cephalgias, migraines and vascular conditions
DE602004007225T2 (de) Methode zur behandlung von erkrankungen der unteren harnwege
US11026882B2 (en) Methods and compositions for treating migraine and conditions associated with pain
ES2275229T3 (es) Metodos para el tratamiento de desordenes del tracto urinario iferior utilizando antimuscarinos y moduladores de la subunidad alfa-2-delta del canal de calcio.
EP1435945B1 (en) Topical migraine therapy
DE69824730T2 (de) Zusammensetzungen, kits und verfahren zur hemmung von zerebralen neurovasculären störungen und muskulärem kopfschmerzen
US20040198775A1 (en) Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using Cav2.2 subunit calcium channel modulators
WO2014020155A1 (en) Oral transmucosal adminstration forms of s-ketamine
EP2481747A1 (en) Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US9012480B2 (en) Topical therapy for migraine
US20110263710A1 (en) Transepithelial methods of using gamma aminobutyric acid compositions for pain relief
HK1169919A (en) Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
HK1169919B (en) Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
US20070105940A1 (en) Method for treating pain
EP3638223B1 (en) Bromhexine for the treatment of pain
US20130338098A1 (en) Topical Analgesic Compositions Containing Aliphatic Polyamines and Methods of Using Same
WO2013002749A1 (en) Transepithelial methods of using gamma aminobutyric acid compositions for pain relief
HK1174049A (en) Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists